Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.

NCT00609947 | Completed Results DMC

• 1 other identifier: IP057
• Study Type: interventional
• Target: 241
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to verify the safety and efficacy of the Endeavor Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessels ≥ 2.25 mm to ≤ 2.75 mm.

Conditions

Coronary Artery Disease

Outcome Measures

Primary Outcomes (2)

• In-segment Percent Diameter Stenosis at 8 Months Post-procedure

  In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).

  8 months post-procedure

• Major Adverse Cardiac Events (MACE) Rate

  Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.

  12 months post-procedure

Study Arms (1)

Endeavor Zotarolimus-Eluting Coronary Stent

EXPERIMENTAL

Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach

Device: Endeavor Zotarolimus-Eluting Coronary Stent

Interventions

Endeavor Zotarolimus-Eluting Coronary Stent DEVICE

Also known as: Endeavor

Endeavor Zotarolimus-Eluting Coronary Stent

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient is ≥18 years of age.
• The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or positive functional study.
• The patient is an acceptable candidate for Percutaneous Transluminal Coronary Angiography (PTCA), stenting, and emergent Coronary Artery Bypass Grafting (CABG) surgery.
• Female patients of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
• The patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board of the respective clinical site.
• The patient agrees to return to same research facility for all required post-procedure follow-up visits.
• \. The target lesion/vessel must meet the following criteria:
• The patient requires treatment of either:
• A single de novo lesion located in a native coronary artery amenable to treatment with a 2.25mm, 2.5mm or 2.75mm stent, or
• Two de novo lesions located in separate target vessels, with at least one of the target lesions amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent and the second lesion amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent or a 3.0mm or 3.5mm approved Endeavor stent.
• The lesion(s) must be ≤ 27mm in length.
• The lesion(s) must have a stenosis of ≥ 50% and \< 100%.
• The vessel(s) has (have) a thrombolysis in myocardial infarction (TIMI) flow 2 or greater.
• The target vessel reference diameter must be ≥ 2.25mm and ≤ 2.75mm and the second target vessel reference diameter, if present, must be ≥ 2.25mm and ≤ 3.5mm.
• All target lesions can be treated with a Medtronic Endeavor stent.

You may not qualify if:

• Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticlopidine, clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings, or sensitivity to contrast media, which cannot be adequately pre-medicated
• History of allergic reaction or significant sensitivity to drugs such as zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative
• Platelet count \<100,000 cells/mm³ or \>700,000 cells/mm³, or white blood cell count \<3,000 cells/mm³
• Serum creatinine level \>2.0 mg/dl within 7 days prior to index procedure
• Evidence of acute MI within 72 hours of intended index procedure
• Planned PCI of any vessel within 30 days pre or post-index procedure and/or planned PCI of the target vessel(s) within 12 months post-procedure.
• During the index procedure, the target lesion(s) requires treatment with a device other than PTCA prior to stent placement
• History of stroke or transient ischemic attack (TIA) within prior 6 months
• Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months.
• History of bleeding diathesis or coagulopathy or patient will refuse blood transfusions.
• Concurrent medical condition with life expectancy of less than 12 months.
• Any previous or planned treatment of target vessel with anti-restenotic therapies including but not limited to brachytherapy.
• Currently participating in an investigational drug or another device study that has not completed primary endpoint or that clinically interferes with current study endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.
• Documented left ventricular ejection fraction (LVEF) \<30% at most recent evaluation.
• \. Target lesion(s) located in native vessel distal to anastomosis with saphenous vein graft or a left/right internal mammary artery bypass with \>40% diameter stenosis anywhere within graft.

Sponsors & Collaborators

• Medtronic Vascular: lead

Study Sites (1)

AnMed Health Medical Center

Anderson, South Carolina, 29621, United States

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Results Point of Contact

• Title: Lynda Chaplin - Study Manager
• Organization: Medtronic CardioVascular

lynda.chaplin@medtronic.com

(707) 543-5459

Study Officials

• Martin B Leon, MD

  Columbia University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 25, 2008
• First Posted: February 7, 2008
• Study Start: January 1, 2008
• Primary Completion: March 1, 2012
• Study Completion: September 1, 2013
• Last Updated: February 9, 2015
• Results First Posted: January 26, 2015

Record last verified: 2015-01

Locations

US (1)